Regulatory Celcuity gains FDA approval for closely watched breast cancer drug BioPharma DiveStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk.OncologyRead full story pharminent July 15, 2026 (Last updated: July 20, 2026) BioPharma Dive Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Oncology Read full story Post navigation Previous: AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drugNext: J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026